



Igal Moarof

Kontakt

Igal Moarof

Publikationen (4)

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch